Brain Volumes, Cognitive Impairment, and Conjugated Equine Estrogens
Authors:
- Mark A. EspelandMEMark A. Espeland
- Karen L. MargolisKMKaren L. Margolis
- Joseph A. MaldjianJMJoseph A. Maldjian
- for the Women's Health Initiative Memory StudyFSfor the Women's Health Initiative Memory Study
Open Access
- 3 September 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 64A (12) , 1243-1250
Abstract
Postmenopausal conjugated equine estrogens (CEE) therapies increase the risk of cognitive impairment in women aged 65 years or older and are associated with smaller regional brain volumes; however, the link between these two phenomena has not been established. Standardized magnetic resonance imaging was performed on 1,403 women, 1–4 years after they had participated in randomized placebo-controlled clinical trials of CEE-based therapies. Women included in this report were aged 65–80 years and free of dementia and mild cognitive impairment (MCI) when originally enrolled in the trials, which lasted an average of 4–6 years and were conducted at 14 academic U.S. medical centers. The associations that regional brain volumes and ischemic lesion volumes had with the development of cognitive impairment (i.e., dementia or MCI) were contrasted between treatment groups using analyses of covariance. Fifty-three women developed MCI or probable dementia during follow-up. Among women who had been prescribed CEE-based therapies, cognitive impairment was associated with relatively smaller hippocampal (p = .0002) and total brain volumes (p = .03). Qualitatively, these associations appeared to be independent of their level of pretreatment cognitive function. Among women who had been prescribed placebo, these relationships were not evident; instead, cognitive impairment was associated with greater ischemic lesion volume in the frontal lobe (p = .007) and overall (p = .02). A mechanism by which CEE-based postmenopausal hormone therapy induces cognitive impairment appears to be through increased brain atrophy.Keywords
This publication has 32 references indexed in Scilit:
- Postmenopausal hormone therapy and regional brain volumesNeurology, 2009
- Postmenopausal hormone therapy and subclinical cerebrovascular diseaseNeurology, 2009
- Uncovering the mechanisms of estrogen effects on hippocampal functionFrontiers in Neuroendocrinology, 2008
- Computer-Assisted Segmentation of White Matter Lesions in 3D MR Images Using Support Vector MachineAcademic Radiology, 2008
- Enrollment in a Brain Magnetic Resonance Study: Results From the Women’s Health Initiative Memory Study Magnetic Resonance Imaging Study (WHIMS-MRI)Academic Radiology, 2007
- Sex steroids, APOE genotype and the innate immune systemNeurobiology of Aging, 2005
- Midlife Blood Pressure and the Risk of Hippocampal AtrophyHypertension, 2004
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- Estradiol initially enhances but subsequently suppresses (via adrenal steroids) granule cell proliferation in the dentate gyrus of adult female ratsJournal of Neurobiology, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002